Dark Blue Therapeutics LogoDark Blue Therapeutics
Dark Blue Therapeutics Logo

The dark blue therapeutics team

We have assembled a team of passionate, seasoned industry experts with backgrounds that span the breadth of innovative drug development from discovery to approval. The team includes innovators and senior leaders from biotech, large pharmaceutical companies and investment management. Key to the ethos of Dark Blue Therapeutics is that agility and collaboration are core to solving the challenges faced in the creation of novel, transformative medicines.

Alastair MacKinnon read bio

Alastair MacKinnon

Chief Executive Officer

John Pollardread bio

John Pollard

Chief Scientific Officer

Emma Smithread bio

Emma Smith

Chief Financial Officer

Alison Maloneyread bio

Alison Maloney

Head of Biology

Iain Simpsonread bio

Iain Simpson

Head of Chemistry

Graham Craggsread bio

Graham Craggs

Director of Translational and Mechanistic Biology

Lucy Coeread bio

Lucy Coe

Project Manager

Board of directors

read bio

James Carmichael

Board Member, Vice President – Integrative Science, Bristol Myers Squibb

read bio

Nick Dixon - Clegg

Board Member – Partner, Oxford Science Enterprises

read bio

Thomas Hanke

Board Member, Executive Vice President, Head of Academic Partnerships, Evotec

read bio

Alastair MacKinnon

Chief Executive Officer

Executive director

read bio

Matthew Carpenter

Board Observer, Deputy Head of Licensing & Ventures at Oxford University Innovation (OUI)

scientific Advisory board

read bio

Johann de Bono

read bio

Chas Bountra

read bio

Scott Fields

read bio

Christopher Lord

read bio

Andrew Mortlock

read bio

Tim Yap

Dark Blue Therapeutics is deeply embedded in the Oxford science ecosystem with privileged access to world leading science and technology.

Our multiple academic partners sit as part of our project and strategy teams, bringing deep pathway, target and disease insights to our day-to-day operations. We leverage this to enable pioneering therapeutic approaches for our targets and to accelerate our drug discovery engine. In many cases we sponsor proprietary research in the academic labs to take full advantage of the unique platforms our collaborators have established.

Our fully committed, collaborative model enables us to work at the cutting edge of drug discovery science across a range of cancer mechanisms, meaning that we do not have restrictions on the selection of our targets or therapeutic approach, instead we work on the targets with the highest chance of providing transformative medicines.